Sequent Scientific Limited , a prominent player in the life sciences sector, has successfully completed its postal ballot process for a significant corporate transformation. The company's shareholders have overwhelmingly approved the proposed name change and related corporate actions through remote e-voting.

Postal Ballot Results and Shareholder Approval

The postal ballot voting concluded on December 28, 2025, with shareholders demonstrating strong support for the proposed changes. The voting results show exceptional approval rates across both resolutions:

Key Approved Resolutions

Shareholders approved two special resolutions through the postal ballot process:

Resolution 1: Change of company name from 'Sequent Scientific Limited' to 'Viyash Scientific Limited' along with consequential alterations in the Memorandum of Association and Articles of Association.

Resolution 2: Alteration of the Objects Clause of the Memorandum of Association to align with the company's strategic direction.

Voting Participation and Process

The postal ballot process witnessed significant participation from various shareholder categories:

The e-voting process was conducted through the National Securities Depository Limited (NSDL) platform, ensuring transparency and accessibility for all eligible shareholders.

Corporate Transformation Timeline

The postal ballot notice was dispatched on November 28, 2025, following the board's earlier approval of the name change proposal. The remote e-voting period commenced on November 29, 2025, and concluded on December 28, 2025. The resolutions are deemed to have been passed on the last date of remote e-voting.

Strategic Implications

This approval marks a significant milestone in Sequent Scientific's corporate evolution, as the company transitions to the 'Viyash Scientific Limited' identity. The name change reflects the company's strategic alignment with the Viyash brand and supports its positioning in the life sciences sector. The alteration of the Objects Clause provides the company with enhanced flexibility to pursue its business objectives under the new corporate structure.

Sequent Scientific has announced the resignation of VP Ashish Kakabalia from his senior management position, effective December 23, 2025. The pharmaceutical company submitted the resignation intimation to BSE and NSE under Regulation 30 of SEBI Listing Regulations.

Executive Departure Details

Kakabalia served as Vice President - Business Development and Formulation and was designated as Senior Management Personnel. His resignation letter was dated December 23, 2025, making the departure effective immediately.

Regulatory Compliance

The company filed the resignation intimation with both stock exchanges as required under SEBI regulations. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, with the requisite documentation submitted to BSE (Scrip Code: 512529) and NSE (Scrip Code: SEQUENT).

Company Communication

The resignation letter was addressed to CEO Rajaram Narayanan of Alivira Animal Health Ltd. In his resignation communication, Kakabalia mentioned that the decision was made as per mutual discussion and understanding, expressing gratitude and best wishes to the company and its employees.

The pharmaceutical company confirmed that the resignation was processed according to regulatory requirements, with Company Secretary and Compliance Officer Yoshita Vora handling the formal disclosure procedures.